Denali Therapeutics Inc
DNLI17.440USD
+0.290+1.69%
收盘 11/14, 16:00（美东）报价延迟15分钟
2.56B总市值
亏损市盈率 TTM
关于 Denali Therapeutics Inc 公司
Denali Therapeutics Inc. 是一家生物制药公司。该公司专注于开发一系列候选产品，这些产品经过设计可穿过血脑屏障 (BBB)，用于治疗神经退行性疾病和溶酶体贮积症。该公司拥有小分子和生物治疗药物组合，包括七种适应症的七种临床开发候选产品以及临床前治疗候选产品。其三个后期开发项目包括用于治疗粘多糖贮积症 II (MPS II) 的 tividenofusp alfa (DNL310)；用于治疗帕金森病的 BIIB122/DNL151 (LRRK2 抑制剂)；以及用于治疗肌萎缩侧索硬化症 (ALS) 的 DNL343 (eIF2B 激活剂)。SAR443820/DNL788 (RIPK1 抑制剂) 正在针对多发性硬化症 (MS) 的 II 期研究中进行评估。此外，该公司还开展了 TAK-594/DNL593 治疗额颞叶痴呆-颗粒蛋白 (FTD-GRN) 的 I/II 期研究，以及 DNL126 治疗 MPS IIIA (Sanfilippo 综合征) 的 I/II 期研究。
Denali Therapeutics Inc简介
公司代码DNLI
公司名称Denali Therapeutics Inc
上市日期Dec 08, 2017
CEODr. Ryan J. Watts, Ph.D.
员工数量422
证券类型Ordinary Share
年结日Dec 08
公司地址161 Oyster Point Blvd.
城市SOUTH SAN FRANCISCO
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编94080
电话16508668547
网址https://www.denalitherapeutics.com
公司代码DNLI
上市日期Dec 08, 2017
CEODr. Ryan J. Watts, Ph.D.
Denali Therapeutics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Ryan J. Watts, Ph.D.
Dr. Ryan J. Watts, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.46M
--
Dr. Alexander O. Schuth, M.D.
Dr. Alexander O. Schuth, M.D.
Chief Operating and Financial Officer, Secretary
Chief Operating and Financial Officer, Secretary
765.12K
-0.38%
Mr. Jay T. Flatley
Mr. Jay T. Flatley
Independent Director
Independent Director
352.53K
+1.74%
Dr. David P. Schenkein, M.D.
Dr. David P. Schenkein, M.D.
Independent Director
Independent Director
72.72K
+9.05%
Mr. Peter S. Klein
Mr. Peter S. Klein
Independent Director
Independent Director
27.53K
+28.08%
Ms. Jennifer E. Cook
Ms. Jennifer E. Cook
Independent Director
Independent Director
26.07K
+30.13%
Dr. Marc Tessier-Lavignec, Ph.D.
Dr. Marc Tessier-Lavignec, Ph.D.
Independent Director
Independent Director
--
--
Mr. Steven E. (Steve) Krognes
Mr. Steven E. (Steve) Krognes
Director
Director
--
--
Ms. Nancy A. Thornberry
Ms. Nancy A. Thornberry
Independent Director
Independent Director
--
--
Mr. Julian C. Baker
Mr. Julian C. Baker
Independent Chairman of the Board
Independent Chairman of the Board
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Ryan J. Watts, Ph.D.
Dr. Ryan J. Watts, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.46M
--
Dr. Alexander O. Schuth, M.D.
Dr. Alexander O. Schuth, M.D.
Chief Operating and Financial Officer, Secretary
Chief Operating and Financial Officer, Secretary
765.12K
-0.38%
Mr. Jay T. Flatley
Mr. Jay T. Flatley
Independent Director
Independent Director
352.53K
+1.74%
Dr. David P. Schenkein, M.D.
Dr. David P. Schenkein, M.D.
Independent Director
Independent Director
72.72K
+9.05%
Mr. Peter S. Klein
Mr. Peter S. Klein
Independent Director
Independent Director
27.53K
+28.08%
Ms. Jennifer E. Cook
Ms. Jennifer E. Cook
Independent Director
Independent Director
26.07K
+30.13%
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 9月29日 周一
更新时间: 9月29日 周一
持股股东
股东类型
持股股东
持股股东
占比
The Vanguard Group, Inc.
8.15%
Baillie Gifford & Co.
7.90%
BlackRock Institutional Trust Company, N.A.
6.91%
Fidelity Management & Research Company LLC
5.05%
Biogen Inc
4.88%
其他
67.11%
持股股东
持股股东
占比
The Vanguard Group, Inc.
8.15%
Baillie Gifford & Co.
7.90%
BlackRock Institutional Trust Company, N.A.
6.91%
Fidelity Management & Research Company LLC
5.05%
Biogen Inc
4.88%
其他
67.11%
股东类型
持股股东
占比
Investment Advisor
55.46%
Investment Advisor/Hedge Fund
22.66%
Hedge Fund
11.87%
Sovereign Wealth Fund
6.34%
Individual Investor
4.92%
Corporation
4.88%
Research Firm
2.13%
Pension Fund
0.50%
Bank and Trust
0.36%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
524
145.41M
99.14%
-6.39M
2025Q2
524
153.05M
105.35%
-12.26M
2025Q1
537
151.12M
104.03%
-14.77M
2024Q4
523
145.56M
100.28%
-21.13M
2024Q3
518
152.07M
106.51%
-14.19M
2024Q2
504
147.18M
103.45%
-5.80M
2024Q1
491
145.33M
102.36%
+2.75M
2023Q4
499
138.06M
99.94%
+3.21M
2023Q3
492
132.50M
96.48%
-2.55M
2023Q2
504
131.32M
95.95%
-3.31M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
11.78M
8.06%
+10.98K
+0.09%
Jun 30, 2025
Baillie Gifford & Co.
11.96M
8.18%
-134.72K
-1.11%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
9.87M
6.75%
-168.55K
-1.68%
Jun 30, 2025
Fidelity Management & Research Company LLC
7.41M
5.07%
+125.57K
+1.72%
Jun 30, 2025
Biogen Inc
7.16M
4.89%
-5.60M
-43.89%
Oct 30, 2024
T. Rowe Price Associates, Inc.
6.46M
4.42%
+2.20M
+51.71%
Jun 30, 2025
Wellington Management Company, LLP
5.66M
3.87%
-5.74M
-50.35%
Jun 30, 2025
Temasek Holdings Pte. Ltd.
5.36M
3.66%
--
--
Jun 30, 2025
Capital Research Global Investors
4.75M
3.25%
-14.56K
-0.31%
Jun 30, 2025
State Street Investment Management (US)
4.52M
3.09%
+57.24K
+1.28%
Jun 30, 2025
查看更多
持股ETF
更新时间: 11月6日 周四
更新时间: 11月6日 周四
机构名称
占比
iShares Neuroscience and Healthcare ETF
3.3%
ALPS Medical Breakthroughs ETF
1.26%
Global X Guru Index ETF
1.21%
Virtus LifeSci Biotech Clinical Trials ETF
0.7%
SPDR S&P Biotech ETF
0.68%
Direxion Daily S&P Biotech Bull 3X Shares
0.36%
Global X Aging Population ETF
0.33%
iShares Health Innovation Active ETF
0.25%
ProShares Ultra Nasdaq Biotechnology
0.22%
Invesco Nasdaq Biotechnology ETF
0.21%
查看更多
iShares Neuroscience and Healthcare ETF
占比3.3%
ALPS Medical Breakthroughs ETF
占比1.26%
Global X Guru Index ETF
占比1.21%
Virtus LifeSci Biotech Clinical Trials ETF
占比0.7%
SPDR S&P Biotech ETF
占比0.68%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.36%
Global X Aging Population ETF
占比0.33%
iShares Health Innovation Active ETF
占比0.25%
ProShares Ultra Nasdaq Biotechnology
占比0.22%
Invesco Nasdaq Biotechnology ETF
占比0.21%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
